Quantum BioPharma Ltd. (NASDAQ: QNTM) has received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application to initiate a Phase 2 clinical trial of Lucid-MS, a first-in-class drug candidate for multiple sclerosis. The randomized, double-blind, placebo-controlled trial will evaluate Lucid-MS in people with MS, representing the first time the compound will be tested in patients with the disease.
Lucid-MS, also known as Lucid-21-302, is a patented small molecule designed to inhibit peptidyl arginine deiminase 2 (PAD2). Unlike current MS therapies that broadly suppress the immune system, Lucid-MS aims to target demyelination—the underlying mechanism of MS—by preventing and reversing myelin degradation. This novel mechanism could offer a safer and more targeted approach for patients who do not respond adequately to existing treatments or who experience significant side effects from immunosuppression.
The FDA clearance follows the completion of Phase 1 testing in healthy volunteers, where the company reported favorable safety and tolerability. Quantum BioPharma is also collaborating with scientists at Massachusetts General Hospital and Harvard Medical School on a parallel research project involving a PET imaging tracer designed to quantify demyelination. This imaging tool could enhance the ability to monitor disease progression and treatment response in MS patients.
Analyst attention has also turned to Quantum BioPharma. Rodman & Renshaw recently initiated coverage on the company with a Buy rating and an $8 price target, reflecting optimism about Lucid-MS as it advances toward its first clinical testing in people with MS. The Phase 2 trial will be a critical test of the drug's potential to address a major unmet need in MS, a chronic neurological disease affecting millions worldwide.
The broader biopharmaceutical landscape has seen significant developments in neurological and autoimmune diseases, with companies such as Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB), and Clene Inc. (NASDAQ: CLNN) also pursuing treatments in this space. Quantum BioPharma's progress with Lucid-MS adds a promising new approach that could complement or compete with existing therapies.
For investors and industry leaders, the FDA clearance de-risks the next stage of development for Quantum BioPharma's lead asset. A successful Phase 2 trial could position Lucid-MS as a breakthrough therapy, potentially attracting partnership interest or accelerating the company's path to commercialization. The trial's results will be closely watched by the MS community and the biotech investment sector.
Quantum BioPharma's pipeline also includes UNBUZZD, a product for alcohol misuse, which has been spun out into Unbuzzd Wellness Inc., with Quantum retaining a 19.84% ownership stake as of March 31, 2026, and royalty rights. However, the primary near-term value driver remains Lucid-MS, and its progression into Phase 2 is a key milestone for the company.
To view the full press release, visit https://ibn.fm/cwPHa. For more information on Quantum BioPharma, visit their newsroom at https://ibn.fm/QNTM.
